KZA Stock Overview
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs.
+ 1 more risk
Kazia Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.25|
|52 Week High||AU$1.65|
|52 Week Low||AU$0.23|
|1 Month Change||-56.90%|
|3 Month Change||-64.54%|
|1 Year Change||-79.84%|
|3 Year Change||-28.57%|
|5 Year Change||-40.48%|
|Change since IPO||-92.65%|
Recent News & Updates
|KZA||AU Biotechs||AU Market|
Return vs Industry: KZA underperformed the Australian Biotechs industry which returned -3.1% over the past year.
Return vs Market: KZA underperformed the Australian Market which returned -8.5% over the past year.
|KZA Average Weekly Movement||17.4%|
|Biotechs Industry Average Movement||11.7%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||18.0%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: KZA is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: KZA's weekly volatility has increased from 12% to 17% over the past year.
About the Company
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer.
Kazia Therapeutics Fundamentals Summary
|KZA fundamental statistics|
Is KZA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KZA income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||-99.27%|
How did KZA perform over the long term?See historical performance and comparison
Is KZA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for KZA?
Other financial metrics that can be useful for relative valuation.
|What is KZA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does KZA's PS Ratio compare to its peers?
|KZA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
NSB NeuroScientific Biopharmaceuticals
ATX Amplia Therapeutics
KZA Kazia Therapeutics
Price-To-Sales vs Peers: KZA is good value based on its Price-To-Sales Ratio (2.3x) compared to the peer average (20x).
Price to Earnings Ratio vs Industry
How does KZA's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales vs Industry: KZA is good value based on its Price-To-Sales Ratio (2.3x) compared to the Australian Biotechs industry average (20x)
Price to Sales Ratio vs Fair Ratio
What is KZA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.3x|
|Fair PS Ratio||24.9x|
Price-To-Sales vs Fair Ratio: KZA is good value based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (24.9x).
Share Price vs Fair Value
What is the Fair Price of KZA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: KZA (A$0.25) is trading below our estimate of fair value (A$16.97)
Significantly Below Fair Value: KZA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Kazia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KZA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KZA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KZA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KZA's revenue (47.8% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: KZA's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: KZA's Return on Equity is forecast to be very high in 3 years time (63.6%).
Discover growth companies
How has Kazia Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KZA is currently unprofitable.
Growing Profit Margin: KZA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KZA is unprofitable, and losses have increased over the past 5 years at a rate of 6.3% per year.
Accelerating Growth: Unable to compare KZA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KZA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.7%).
Return on Equity
High ROE: KZA has a negative Return on Equity (-59.16%), as it is currently unprofitable.
Discover strong past performing companies
How is Kazia Therapeutics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: KZA's short term assets (A$16.7M) exceed its short term liabilities (A$7.6M).
Long Term Liabilities: KZA's short term assets (A$16.7M) exceed its long term liabilities (A$11.6M).
Debt to Equity History and Analysis
Debt Level: KZA is debt free.
Reducing Debt: KZA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KZA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KZA has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.1% each year.
Discover healthy companies
What is Kazia Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KZA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate KZA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KZA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KZA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as KZA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
James Garner (49 yo)
Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1,...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD804.49K) is above average for companies of similar size in the Australian market ($USD285.93K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Experienced Management: KZA's management team is seasoned and experienced (5.4 years average tenure).
Experienced Board: KZA's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.5%.
Kazia Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Kazia Therapeutics Limited
- Ticker: KZA
- Exchange: ASX
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: AU$34.832m
- Shares outstanding: 139.33m
- Website: https://www.kaziatherapeutics.com
- Kazia Therapeutics Limited
- Three International Towers
- Level 24
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/13 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.